<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alpha thalassemia major: Prenatal and postnatal management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alpha thalassemia major: Prenatal and postnatal management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Alpha thalassemia major: Prenatal and postnatal management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ashutosh Lal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Billie R Lianoglou, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan M Gonzalez Velez, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elliott P Vichinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2567452155"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alpha thalassemia major (ATM; deletion of all four alpha globin genes) was once considered incompatible with life. However, advances in prenatal and postnatal care have resulted in viability and good quality of life for an increasing number of individuals.</p><p>This topic discusses management of ATM from conception through early childhood. </p><p>Management of beta thalassemia and less-severe forms of alpha thalassemia are presented separately. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia"</a> and  <a class="medical medical_review" href="/d/html/3554.html" rel="external">"Hematopoietic stem cell transplantation for transfusion-dependent thalassemia"</a>.)</p><p class="headingAnchor" id="H613025515"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2281915824"><span class="h2">Disease definition</span><span class="headingEndMark"> — </span>Alpha thalassemias are caused by reductions in alpha globin chains. (See  <a class="medical medical_review" href="/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes"</a>.)</p><p>Alpha globin is produced from two genes on chromosome 16, <em>HBA1</em> and <em>HBA2</em>. Individuals normally possess four alpha globin genes (two from each parent); the genotype can be represented as αα/αα. Depending on the maternal and paternal genotypes, an individual can have pathogenic variants that affect one, two, three, or four alpha globin loci. These alpha globin variants decrease the production of alpha globin, leading to an imbalance in the ratio of alpha to beta globin chains. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Four gene deletion (ATM)</strong> – ATM results from deletion of all four alpha globin genes (--/--) [<a href="#rid1">1</a>]. This condition is also known as homozygous alpha<sup>0</sup> thalassemia and is a cause of fetal effusions (pericardial, pleural, skin edema and ascites) resulting in nonimmune hydrops fetalis. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Anemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Two or three gene deletion (Hb H disease)</strong> – Prenatal phenotypes including fetal effusions can also be caused by other alpha thalassemia genotypes including nondeletional or unstable alpha globin variants, even in the presence of one or two normal alpha genes (--/α<sup>T</sup>α or -α<sup>T</sup>/-α<sup>T</sup>). This condition, which is less common than ATM, is known as hemoglobin H hydrops fetalis. It is more severe in the intrauterine period. The postnatal course is highly variable depending upon the genotype, ranging from a nontransfusion-dependent moderate anemia to transfusion dependence [<a href="#rid2">2-4</a>]. Knowledge of the fetal genotype is important for determining prognosis and counseling the parents. (See <a class="local">'Counseling and decision-making'</a> below.)</p><p></p><p>Definitions of beta thalassemia syndromes and less-severe alpha thalassemia syndromes are presented separately. (See  <a class="medical medical_review" href="/d/html/7090.html" rel="external">"Pathophysiology of thalassemia", section on 'Terminology and disease classification'</a>.)</p><p class="headingAnchor" id="H2785064551"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>ATM is a common condition in many regions of the world, especially Southern China, Malaysia, and Thailand, where ≥5 percent of the population can be carriers of alpha<sup>0</sup> thalassemia (deletion of two alpha genes on the same chromosome [--/αα]). (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Epidemiology'</a>.)</p><p>The number of pregnancies affected by ATM is vastly more than the number of reported births. </p><p>The number of live births with ATM is low but increasing, often with acutely ill newborns. In areas of Southeast Asia where alpha thalassemia is prevalent, an expected 4500 pregnancies with ATM occur annually [<a href="#rid5">5</a>]. </p><p>With immigration, the prevalence of alpha thalassemia continues to increase in North America and Europe [<a href="#rid6">6</a>]. Newborn screening data from California found 1 in 87 newborns have Southeast Asian ancestry and 1 in 10,417 newborns have a clinically significant alpha thalassemia syndrome (ATM, Hb H disease, or Hb H/Hb Constant Spring) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1013731632"><span class="h1">PRENATAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1861168799"><span class="h2">Timing of onset</span><span class="headingEndMark"> — </span>Since alpha globin chains are required for synthesis of fetal hemoglobin (Hb F), manifestations of alpha thalassemia begin during the prenatal period. (See  <a class="medical medical_review" href="/d/html/7090.html" rel="external">"Pathophysiology of thalassemia", section on 'Globin chain imbalance'</a>.) </p><p>Complications specific to ATM include profound fetal anemia, a high proportion of nonfunctional Hb Barts (gamma globin tetramers), often &gt;80 percent of total hemoglobin, along with massive organomegaly, thrombocytopenia, abnormal liver function, and congenital anomalies. (See <a class="local">'Fetal complications'</a> below.)</p><p>Anemia and Hb Barts develop as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Embryo </strong>– Embryonic viability depends upon the preservation of zeta globin genes (ζ --/ ζ --, or - --/ ζ --). Zeta globin is upstream of the two alpha globin genes in the alpha globin gene cluster on chromosome 16  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). Preservation of zeta globin occurs in a subset of deletions (ζ --); the most frequent of which is the Southeast Asian deletion (--<sup>SEA</sup>). (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetus</strong> – Early fetal development is supported by Hb Portland (ζ<sub>2</sub>γ<sub>2</sub>) and other embryonic hemoglobins up to approximately 14 weeks of gestation. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a>.)</p><p></p><p class="bulletIndent1">Subsequently, gene switching from zeta to alpha globin reduces the level of zeta gene expression, and a profound fetal anemia ensues from the failure to synthesize alpha globin chains [<a href="#rid8">8-10</a>]. </p><p></p><p class="bulletIndent1">In the absence of normal alpha globin chains to pair with gamma globin chains, the gamma globin chains self-associate into tetramers (γ<sub>4</sub>), referred to as Hb Barts, which is the main hemoglobin in a fetus with ATM. </p><p></p><p class="bulletIndent1">Hb Barts has extremely high oxygen affinity, which renders it ineffective in oxygen transport from placenta to fetal tissues. Consequently, most pregnancies that are not treated with fetal transfusions are nonviable (Hb Barts hydrops fetalis). If fetal ultrasound is not performed, the pregnancy continues without a diagnosis, resulting in fetal demise or neonatal death shortly after delivery in most cases. </p><p></p><p class="bulletIndent1">Spontaneous survivors have been reported after a medically unstable neonatal period. Genotype-phenotype correlations have been proposed that suggest the value of preservation of zeta globin expression in these survivors [<a href="#rid11">11</a>]. Cord hemoglobin is approximately 6 g/dL, with Hb Portland comprising 17 percent of the total. </p><p></p><p class="bulletIndent1">In contrast, actively managed pregnancies with early prenatal diagnosis and intrauterine transfusions (IUT) can produce viable offspring. Perinatal and postnatal events are heavily influenced by the adequacy of prenatal transfusion management, as discussed below. (See <a class="local">'Fetal testing'</a> below and <a class="local">'Intrauterine transfusions'</a> below.)</p><p></p><p class="headingAnchor" id="H1896777111"><span class="h2">Fetal complications</span></p><p class="headingAnchor" id="H548037366"><span class="h3">Anemia and hyperbilirubinemia</span><span class="headingEndMark"> — </span>In the absence of any intervention, the fetus develops severe anemia with an average midgestation hemoglobin 6.4 g/dL, most of which is the nonfunctional Hb Barts. This is an important distinction from the anemia in immune hydrops due to hemolytic disease of the fetus and newborn (HDFN), where the predominant hemoglobin species (Hb F) has a normal capacity for oxygen transport. </p><p>The profound fetal anemia and hypoxia in ATM is associated hydrops, characterized by organomegaly, severe hypoalbuminemia, cardiomegaly, heart failure, ascites, pleural and pericardial effusions, edema, and growth failure, often followed by fetal demise. </p><p>Hemolysis and hyperbilirubinemia are typically present but are less severe than observed in newborns with immune hydrops fetalis due to HDFN. </p><p class="headingAnchor" id="H85276807"><span class="h3">Abnormal liver function tests</span><span class="headingEndMark"> — </span>Transaminases are frequently increased, presumably from intrauterine cardiac decompensation and hypoxia. </p><p class="headingAnchor" id="H812677912"><span class="h3">Thrombocytopenia</span><span class="headingEndMark"> — </span>Thrombocytopenia is observed in newborns born with hydropic features. This is probably caused by platelet consumption in an enlarged spleen. (See  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Hypersplenism'</a>.)</p><p class="headingAnchor" id="H4281665970"><span class="h3">Congenital anomalies</span><span class="headingEndMark"> — </span>Urogenital anomalies are present in most males with ATM; hypospadias is most common [<a href="#rid11">11-14</a>]. Other abnormalities are undescended testes, bifid scrotum, hydrocele, and micropezid. (See  <a class="medical medical_review" href="/d/html/6583.html" rel="external">"Hypospadias: Pathogenesis, diagnosis, and evaluation"</a>.)</p><p>Limb anomalies are also seen in 16 percent but tend to be mild [<a href="#rid12">12</a>]. Approximately 10 percent of patients have atrial septal defect. Other anomalies are rare and not clearly associated with ATM. </p><p>The incidence of congenital anomalies is not affected by IUT, which suggests that hypoxia during organogenesis may be a factor [<a href="#rid11">11,15</a>]. </p><p class="headingAnchor" id="H1182482945"><span class="h3">Neurodevelopmental delay</span><span class="headingEndMark"> — </span>Neurodevelopmental delay can present as speech and hearing difficulties, motor delay, spastic quadriplegia, and global developmental delay. In an international registry including 55 individuals evaluated for neurodevelopmental delay, 11 (20 percent) had a delay of ≥6 months [<a href="#rid11">11</a>]. </p><p>Emerging evidence supports the value of IUT to preserve neurodevelopment, as discussed below. (See <a class="local">'Intrauterine transfusions'</a> below.)</p><p class="headingAnchor" id="H1941797860"><span class="h2">Maternal complications</span><span class="headingEndMark"> — </span>Pregnancy with a fetus with hydrops fetalis can cause mirror syndrome, characterized by the maternal edema, proteinuria, and hypertension. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Mirror syndrome'</a>.)</p><p>Other potential maternal complications include dystocia, postpartum hemorrhage due to placental enlargement, and, for those who forgo fetal therapy, the psychological burden of carrying a nonviable fetus [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/6740.html" rel="external">"Stillbirth: Maternal care", section on 'Grief and bereavement'</a>.)</p><p>The risk of mirror syndrome and other maternal complications can be reduced with IUT. (See <a class="local">'Intrauterine transfusions'</a> below.)</p><p class="headingAnchor" id="H894862537"><span class="h1">PRENATAL SCREENING AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Most couples are unaware of their risk for thalassemia in pregnancy. Ideally, screening for thalassemia (and other hemoglobinopathies) occurs during preconception counseling. (See  <a class="medical medical_review" href="/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p class="headingAnchor" id="H890006599"><span class="h2">Maternal and partner testing</span><span class="headingEndMark"> — </span>The complete blood count (CBC) is assessed on the mother's initial prenatal laboratory testing. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mother</strong> – Thalassemia trait is suggested when microcytic anemia is present in females during pregnancy irrespective of whether iron stores are replete. Screening for iron deficiency or iron deficiency anemia is a routine component of prenatal care. (See  <a class="medical medical_review" href="/d/html/115637.html" rel="external">"Anemia in pregnancy", section on 'Screening during pregnancy'</a>.)</p><p></p><p class="bulletIndent1">We evaluate for thalassemia trait using maternal hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) and simultaneous alpha globin gene testing with polymerase chain reaction (PCR) to detect common deletions. This is because normal hemoglobin electrophoresis or HPLC results do not exclude alpha thalassemia, and it is important to distinguish between alpha<sup>+</sup> thalassemia trait (deletion of one of the two alpha globin genes on a chromosome) from alpha<sup>0</sup> thalassemia trait (deletion of both alpha globin genes on the same chromosome), which determines the risk of ATM in the fetus. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Alpha thalassemias'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partner</strong> – Partner testing is also essential to determine fetal risk. If the father does not have alpha<sup>0</sup> thalassemia trait and paternity is assured, then the fetus will not have ATM, although a less-severe form of thalassemia may be inherited from the mother. </p><p></p><p>If both parents have an alpha<sup>0</sup> thalassemia trait, with deletion of both alpha globin genes on the same chromosome (--/αα) or (--/-α), then the fetus is at risk for ATM  (<a class="graphic graphic_table graphicRef115337" href="/d/graphic/115337.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/138739.html" rel="external">"Gene test interpretation: <i>HBA1 </i>and <i>HBA2 </i>(alpha globin genes)"</a>.)</p><p>Couples at risk for ATM in pregnancy should be educated regarding reproductive options including in vitro fertilization (IVF) with preimplantation genetic testing (PAT), as well as the risks, benefits, and limitations of pregnancy management options including termination of pregnancy (when available), active fetal management, and expectant management [<a href="#rid17">17</a>]. (See <a class="local">'Counseling and decision-making'</a> below and  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p class="headingAnchor" id="H4053939881"><span class="h2">Fetal testing</span><span class="headingEndMark"> — </span>Prenatal diagnosis should be offered to all patients whose fetus is at risk for ATM. For patients electing to proceed with active management, given the relatively low risk of invasive testing, the benefits of early prenatal diagnosis to allow for early introduction of fetal therapy should be emphasized. </p><p class="headingAnchor" id="H2975703825"><span class="h3">Molecular prenatal diagnosis</span><span class="headingEndMark"> — </span>Procedures for fetal testing include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chorionic villus sampling</strong> – A small sample of placental tissue is obtained either transcervically or transabdominally under ultrasound guidance. This procedure is usually performed between 10 and 14 weeks. (See  <a class="medical medical_review" href="/d/html/449.html" rel="external">"Chorionic villus sampling"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amniocentesis</strong> – Amniotic fluid is removed via a needle placed in the amniotic cavity under ultrasound guidance. It is usually performed after 15 weeks' gestation. (See  <a class="medical medical_review" href="/d/html/5390.html" rel="external">"Diagnostic amniocentesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal blood sampling</strong> – Percutaneous umbilical blood sampling (PUBS; cordocentesis) is performed under direct ultrasound guidance with a needle obtaining a fetal blood sample from the umbilical vein. The earliest gestational age PUBS is usually performed is 18 weeks. This may be used to simultaneously confirm fetal anemia and treat with intrauterine red blood cell (RBC) transfusion [<a href="#rid18">18-20</a>]. (See <a class="local">'Intrauterine transfusions'</a> below and  <a class="medical medical_review" href="/d/html/5389.html" rel="external">"Fetal blood sampling"</a>.)</p><p></p><p>Molecular testing can be performed on any of the above specimens, including fetal DNA extracted from the fetal cord blood sample. Evaluation of Hb Barts (&gt;80 percent) from the cordocentesis sample may also be useful in the diagnosis of an affected fetus. </p><p class="headingAnchor" id="H491000236"><span class="h3">Fetal ultrasound</span><span class="headingEndMark"> — </span>In patients at risk for having a fetus with ATM who do not proceed with prenatal diagnosis, ultrasound may be used to detect features consistent with a diagnosis of ATM. (See  <a class="medical medical_review" href="/d/html/5388.html" rel="external">"Overview of ultrasound examination in obstetrics and gynecology", section on 'Obstetric sonography'</a>.)</p><p>Ultrasound findings in ATM include:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased cardiothoracic ratio (≥0.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Enlarged placenta (&gt;18 mm before 15 weeks and &gt;30 mm after 18 weeks)</p><p class="bulletIndent1"><span class="glyph">●</span>Signs of hydrops (fluid collection in any one compartment including pericardial effusion, pleural effusion, ascites, or skin edema)</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated middle cerebral artery peak systolic velocity (MCA PSV)</p><p class="bulletIndent1"><span class="glyph">●</span>Amniotic fluid abnormalities (oligohydramnios and polyhydramnios)</p><p class="bulletIndent1"><span class="glyph">●</span>In our practice, we have also observed fetal growth restriction and echogenic bowel</p><p></p><p>An MCA PSV &gt;1.5 multiples of the median (MoM) for gestational age is suggestive of moderate to severe anemia. However, MCA PSV is less reliable for assessing anemia in alpha thalassemia compared with other anemias, especially in early pregnancy [<a href="#rid21">21-23</a>]. </p><p class="headingAnchor" id="H3222474350"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of ATM is confirmed by the finding of deletion of all four alpha globin genes (--/--), typically by alpha globin gene PCR. (See <a class="local">'Disease definition'</a> above.)</p><p>In unsuspected cases, the prenatal diagnosis of ATM is usually made by the observation of hydrops on fetal ultrasound during the second trimester. This must be followed by an evaluation for the cause. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Postdiagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H2362465981"><span class="h1">COUNSELING AND DECISION-MAKING</span><span class="headingEndMark"> — </span>Confirmed diagnosis of ATM is followed by nondirective counseling to decide between continuation of pregnancy or termination [<a href="#rid17">17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuation with fetal therapy</strong> – If the pregnancy is continued, the adequacy of prenatal management strongly influences the perinatal and postnatal course [<a href="#rid9">9,13-15</a>]. Collaborative management by fetal medicine specialists and hematologists are essential to attain safe post-transfusion hemoglobin targets and suppress Hb Barts. Fetal hydrops resolve with effective intrauterine transfusion (IUT) regimens, and delivery is more likely to occur close to term, which markedly reduces neonatal complications. (See <a class="local">'Management (prenatal and neonatal)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Termination</strong> – Most pregnancies are terminated due to concerns over maternal health, technical difficulties in supporting IUTs, the prospect of lifelong transfusion dependence following a live birth, and the risk of poor neurodevelopmental outcome. A 2023 case series reported a termination rate of up to 61 percent [<a href="#rid24">24</a>]. (See <a class="local">'Neurodevelopmental delay'</a> above and  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuation without fetal therapy</strong> – In some instances, the parents may decide to continue the pregnancy without fetal therapy. These individuals should be monitored closely due to the risks of mirror syndrome. (See <a class="local">'Maternal complications'</a> above.) </p><p></p><p>Education about options for future pregnancy should also be provided, including the use of in vitro fertilization (IVF) with preimplantation genetic testing for a monogenic disorder (PGT-M). (See  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p>Less severe forms of thalassemia do not require intensive fetal management and can be addressed after delivery. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/138739.html" rel="external">"Gene test interpretation: <i>HBA1 </i>and <i>HBA2 </i>(alpha globin genes)"</a>.)</p><p class="headingAnchor" id="H2190414278"><span class="h1">MANAGEMENT (PRENATAL AND NEONATAL)</span></p><p class="headingAnchor" id="H778222671"><span class="h2">Prenatal</span></p><p class="headingAnchor" id="H4244898581"><span class="h3">Intrauterine transfusions</span><span class="headingEndMark"> — </span>Providing intrauterine transfusions (IUT) is the major prenatal intervention for ATM. Data from case series of active management of ATM provide support for early initiation of optimally provided IUT therapy to improve long-term outcomes. Acceptance of IUT followed by chronic transfusions after birth has increased following the observation of major improvements in the survival and quality of life of people with beta thalassemia major. However, despite the value of IUT, a 2021 consensus document reported that many individuals carrying a pregnancy with ATM are not offered this intervention [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to start</strong> – For patients electing to proceed with fetal therapy, IUT should be initiated as soon as technically possible (18 weeks at most fetal treatment centers) to reverse or prevent overt fetal and/or maternal complications due to anemia [<a href="#rid17">17</a>]. In cases where IUT is not feasible, intraperitoneal transfusions may be an alternative. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goal of therapy</strong> – The goal of IUT regimen should be to achieve total hemoglobin 11 to 13 g/dL with Hb Barts &lt;20 percent at birth. (See <a class="local">'Delivery and neonatal period'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IUT protocol </strong>– The protocol for IUTs is similar to standard protocols used for hemolytic disease of the fetus and newborn (HDFN), with the following exceptions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In ATM, the fetal hematocrit does not represent the amount of functional hemoglobin in fetal red blood cells (RBCs). This is because the major hemoglobin, Hb Barts, which accounts for nearly 100 percent of hemoglobin in the fetus, is functionally useless in oxygen delivery due to its extremely high oxygen affinity, which prevents oxygen release to fetal tissues. The optimal protocol establishing the transfusion volume for the treatment of fetuses affected with ATM remains an area of continued research. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do not administer <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, as is done by some experts for fetuses with HDFN. This is because severe hyperbilirubinemia does not occur in ATM. (See  <a class="medical medical_review" href="/d/html/5385.html" rel="external">"Intrauterine fetal transfusion of red blood cells", section on 'Phenobarbital'</a>.)</p><p></p><p class="bulletIndent1">In our practice, we perform percutaneous fetal blood sampling (PUBS) with IUT every two to three weeks after the initial transfusion. (See  <a class="medical medical_review" href="/d/html/5389.html" rel="external">"Fetal blood sampling", section on 'Umbilical cord blood sampling'</a> and  <a class="medical medical_review" href="/d/html/5385.html" rel="external">"Intrauterine fetal transfusion of red blood cells", section on 'Calculating transfusion volume'</a>.)</p><p></p><p class="bulletIndent1">Details of preparation (crossmatching, role of irradiation, washing) and technique (accessing the umbilical vein) are discussed separately. (See  <a class="medical medical_review" href="/d/html/5385.html" rel="external">"Intrauterine fetal transfusion of red blood cells"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> –<strong> </strong>Evidence for the benefits of IUT continue to emerge [<a href="#rid13">13-15,24</a>]. Adequate IUT started early in gestation can prevent most neonatal complications (except congenital anomalies). (See <a class="local">'Delivery and neonatal period'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2023 cohort of 19 singleton pregnancies with ATM that were not terminated, all of the 14 fetuses treated with two or more IUTs survived to delivery, and all five fetuses not treated with IUT died in utero or shortly after birth [<a href="#rid24">24</a>]. Analysis of these and other data concluded that compared with zero to one IUTs, receipt of two or more IUTs was associated with greater resolution of fetal hydrops, greater likelihood of delivery at 34 weeks or later, and greater likelihood of normal neurodevelopmental scores. Neurodevelopmental scores were normal in 17 of 18 recipients of ≥2 IUTs (94 percent) versus 5 of 13 recipients of 0 to 1 IUT (38 percent). The earlier the IUT was initiated, the higher the neurodevelopmental scores. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2021 cohort of 25 pregnancies with ATM that were not terminated, most cases using IUT prior to 28 weeks resulted in survival with full resolution of hydrops at delivery [<a href="#rid14">14</a>]. Of the 12 fetuses not treated with IUT, none survived. Four fetuses were treated with IUT starting after 28 weeks: two survived and two died due to complications of hydrops at delivery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2016 review of outcomes following IUT in 14 pregnancies with hydrops fetalis demonstrated generally favorable outcomes, with mild developmental delays in 4 (29 percent) and normal neurodevelopmental assessment in 10 (71 percent) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active management with IUT that resolves fetal hydrops and should in turn reduce the overall risk for maternal complications such as mirror syndrome [<a href="#rid14">14,24,25</a>]. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Maternal findings'</a> and  <a class="medical medical_review" href="/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations", section on 'Management of polyhydramnios in singleton pregnancies'</a>.)</p><p></p><p class="headingAnchor" id="H1576164125"><span class="h3">Intrauterine hematopoietic stem cell transplant</span><span class="headingEndMark"> — </span>Intrauterine haploidentical hematopoietic stem cell transplant (HSCT) using maternal bone marrow enriched for CD34+ cells is being studied in a phase I clinical trial. Maternal hematopoietic stem cells are administered as a one-time infusion immediately before the RBC transfusion through the umbilical vein at the time of IUT [<a href="#rid26">26</a>]. </p><p>Transplant after birth is discussed below. (See <a class="local">'Hematopoietic stem cell transplant'</a> below.)</p><p class="headingAnchor" id="H303590287"><span class="h2">Delivery and neonatal period</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks</strong> – Delivery should occur in a facility that can provide high-level critical care. Typically, this involves a tertiary care center with specialized perinatology, pediatric hematology, and/or neonatology teams that can provide emergency management if needed [<a href="#rid17">17</a>]. Some neonates may need aggressive resuscitation and mechanical ventilation at birth, although this can generally be precluded by an adequate IUT program.</p><p></p><p class="bulletIndent1">Newborn infants with ATM are at risk for severe complications, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preterm birth with fetal growth restriction</p><p class="bulletIndent2"><span class="glyph">•</span>Cesarean birth </p><p class="bulletIndent2"><span class="glyph">•</span>Birth trauma</p><p class="bulletIndent2"><span class="glyph">•</span>Intracranial hemorrhage</p><p class="bulletIndent2"><span class="glyph">•</span>Difficult resuscitation with need for intubation</p><p class="bulletIndent2"><span class="glyph">•</span>Need for mechanical ventilatory support</p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory distress syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Persistent pulmonary hypertension</p><p class="bulletIndent2"><span class="glyph">•</span>Patent ductus arteriosus, cardiorespiratory collapse, organomegaly with effusions and ascites, thrombocytopenia, and hyperbilirubinemia</p><p></p><p class="bulletIndent1">Most of these neonatal complications (except congenital anomalies) can be prevented with adequate IUT starting early during gestation. (See <a class="local">'Intrauterine transfusions'</a> above.)</p><p></p><p class="bulletIndent1">General management of the hydropic newborn is presented separately. (See  <a class="medical medical_review" href="/d/html/5027.html" rel="external">"Nonimmune hydrops fetalis in the neonate: Causes, presentation, and overview of neonatal management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cord blood sample</strong> – Cord blood hemoglobin and Hb Barts are tested at birth. Hb Barts can be measured by electrophoresis or high-performance liquid chromatography (HPLC). This may be helpful in appreciating the impact of fetal transfusion to reduce Hb Barts. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delayed cord clamping is not recommended due to the presence of Hb Barts in the fetal (and cord) blood.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The cord blood hemoglobin value will vary based upon the interval from the last IUT. The proportion of Hb Barts at birth depends upon the adequacy of IUT and the duration between last transfusion and birth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent transfusion</strong> – An urgent simple transfusion with 5 to 10 mL/kg of a high-hematocrit RBC unit should be given initially, with subsequent management depending upon the cardiovascular status, cord blood hemoglobin, and proportion of Hb Barts. The purpose of transfusions is to manage anemia and suppress Hb Barts production.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If Hb Barts in cord blood is &lt;50 percent of total hemoglobin, further simple transfusions are sufficient to raise total hemoglobin to &gt;12 g/dL and suppress endogenous erythropoiesis. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If Hb Barts in cord blood is &gt;50 percent, an isovolemic exchange transfusion should be carried out to rapidly lower Hb Barts and improve oxygenation. Further simple transfusions should be carried out to maintain total hemoglobin &gt;12 g/dL while critical care support continues. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is important to measure Hb Barts frequently to maintain it &lt;20 percent of total hemoglobin, which will keep the functional Hb A &gt;10 g/dL at all times. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transition to chronic transfusion program</strong> – Following discharge from the neonatal unit, infants are transitioned to a chronic transfusion program and guidelines for managing infants with ATM should be followed. (See <a class="local">'Chronic transfusion program'</a> below and <a class="local">'Management (infancy and childhood)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phototherapy </strong>– Hyperbilirubinemia can usually be managed with phototherapy if needed. Unlike HDFN, exchange transfusions are typically not required. As the total hemoglobin level is raised by simple transfusions, the decrease in erythropoiesis suppresses bilirubin production. (See  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Initial intervention (phototherapy)'</a>.)</p><p></p><p class="headingAnchor" id="H727643164"><span class="h1">MANAGEMENT (INFANCY AND CHILDHOOD)</span></p><p class="headingAnchor" id="H4030660954"><span class="h2">Chronic transfusion program</span><span class="headingEndMark"> — </span>All infants with ATM are transfusion-dependent from birth. In ATM, transfusions begin in the prenatal period compared with six to nine months after birth in beta thalassemia major. The transition to chronic transfusions lasts until six months of age and is characterized by switch from Hb Barts to Hb H, reduction of hepatosplenomegaly and cardiomegaly, improvement in thrombocytopenia and transaminitis, and establishment of consistent weight gain. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – The purpose of raising the hemoglobin (initially to &gt;12g/dL) is suppression of erythropoiesis, including extramedullary erythropoiesis. Suppression of erythropoiesis assists in reducing splenomegaly, which is necessary to eventually decrease the transfusion volume and frequency. A gradual improvement in cardiomegaly and liver function abnormalities is seen by three to six months after the institution of transfusion therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin targets, schedule, and monitoring</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First three to six months</strong> – During the first three to six months, total pretransfusion hemoglobin is maintained at &gt;12 g/dL, of which the unmeasured, nonfunctional hemoglobin (Hb Barts plus Hb H) is 15 to 20 percent of the total, and the functional Hb A is &gt;10 g/dL. As Hb Barts is gradually replaced by Hb H in the first few months of life, estimating the proportion of these two nonfunctional hemoglobins requires expert laboratory support. It is our practice to send every pretransfusion blood sample for hemoglobin fractionation. RBC antigens should be determined by DNA testing so that antigen-matched blood can be provided to reduce the risk of alloimmunization. (See  <a class="medical medical_review" href="/d/html/7953.html" rel="external">"Pretransfusion testing for red blood cell transfusion", section on 'RBC genotyping'</a>.)</p><p></p><p class="bulletIndent2">The transfusion interval is initially two weeks and gradually increased to three weeks. Smaller infants may require central venous access. Institutional newborn transfusion protocols are followed until three months of age. Close attention to nutrition and caloric intake is essential. Elective medical interventions are postponed to allow time for the parents to bond with the infant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>After six months</strong> – After the first six months, infants transition to the chronic transfusion protocol, which uses the following parameters: pretransfusion Hb A &gt;9 g/dL, transfusion frequency every three to four weeks, and prevention of splenic enlargement. </p><p></p><p class="bulletIndent2">It is important to follow Hb A instead of total hemoglobin in the pretransfusion sample to account for the nonfunctional Hb H. This is an important difference from beta thalassemia major, where the alternate hemoglobin (Hb F) participates in oxygen transport and is counted towards the total hemoglobin; children with ATM are at risk for under-transfusion if guidelines for beta thalassemia major are followed [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent2">The unstable nature of Hb H is a barrier to calculating the absolute Hb A concentration. Accurate measurement of Hb H requires samples to be tested within hours of collection, while overnight or longer storage reduces Hb H level, particularly with refrigeration. This creates a situation where the calculated Hb A level is falsely high and affects calculation of transfusion volume. </p><p></p><p class="bulletIndent2">Infusion centers lacking access to precise Hb H measurements can opt to treat by maintaining pretransfusion total hemoglobin at 10.5 to 11 g/dL and reticulocyte count &lt;500,000/microL [<a href="#rid27">27</a>]. The typical requirement for RBCs stored in additive solution is 16 mL/kg on a three-week schedule and 20 mL/kg on a four-week schedule. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid splenectomy</strong> – Splenectomy is <strong>not</strong> recommended in the management of ATM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet transfusions</strong> – Platelet transfusion support may be necessary during the first week, but spontaneous recovery from thrombocytopenia is seen with improvement in anemia.</p><p></p><p class="headingAnchor" id="H2910873739"><span class="h2">Iron overload and chelation</span><span class="headingEndMark"> — </span>Transfusional iron overload occurs early, within a few months of birth. The assessment and management of iron overload in ATM is not well-defined, and hepatic complications of hydrops fetalis can increase serum ferritin, making it unreliable for determining the degree of iron overload. Initially, liver injury causes ferritin to be elevated out of proportion to iron stores. (See <a class="local">'Abnormal liver function tests'</a> above.)</p><p>Management guidelines from beta thalassemia major suggest that starting chelation therapy after 12 months of transfusions is associated with acceptable long-term outcomes with no permanent iron-induced organ injury. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of initiation</strong> – Transfusion therapy is intensive in infants with ATM, with 16 to 20 transfusions expected within the first 12 months. However, we postpone chelation until 12 months of age, given concerns over inflammation of the liver and immaturity of the kidneys, and the lack of experience with iron chelators during the first year of life. Iron chelating agents are not approved for use in children under two years, but delaying chelation in ATM until two years of age could be harmful. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agent and dose</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Deferasirox</strong><strong> </strong>– We usually start treatment with a low dose of <a class="drug drug_general" data-topicid="8794" href="/d/drug information/8794.html" rel="external">deferasirox</a> (Jadenu, 3 to 5 mg/kg, usually 45 mg, crushed tablet) and increase the dose by 45 mg every two months as long as transaminases are stable. The dose is increased up to a maximum of 14 mg/kg until the child is two years old, following which the general guidelines for deferasirox are followed. (See  <a class="medical medical_review" href="/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Deferiprone</strong> – We reserve <a class="drug drug_general" data-topicid="17092" href="/d/drug information/17092.html" rel="external">deferiprone</a> for situations where <a class="drug drug_general" data-topicid="8794" href="/d/drug information/8794.html" rel="external">deferasirox</a> is not tolerated at therapeutic doses, in which case it can be added as a second chelator at a dose of 50 to 75 mg/kg. Safety and efficacy of deferiprone in children &lt;2 years with beta thalassemia major was reported in abstract form [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Deferoxamine</strong> – <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">Deferoxamine</a> can be used in combination with one of the other chelators in children with severe hepatic iron overload. The dose of deferoxamine is limited to 20 to 30 mg/kg as a subcutaneous infusion on three to five days per week to reduce the risk of toxicity affecting bones and growth [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and toxicities</strong> – The goal of chelation is to maintain serum ferritin in the range of 1000 to 2000 ng/mL in the second year, as attempts to achieve lower ferritin levels may increase the risk of toxicity from chelation. Transaminitis is the limiting toxicity of <a class="drug drug_general" data-topicid="8794" href="/d/drug information/8794.html" rel="external">deferasirox</a> in infants, and it can be difficult to distinguish from other causes of transaminase elevation such as iron overload or acute viral infection. Standard guidelines for monitoring deferasirox include [<a href="#rid30">30</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transaminases, especially alanine aminotransferase (ALT), are monitored every three to four weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney function (eg, creatinine, potassium, bicarbonate, phosphorus) is monitored at least every three to four weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medications and potential drug interactions are reviewed every three to four weeks (more frequently if needed).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urine protein is monitored every three months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Retinal examination is performed annually.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tissue iron burden is monitored using ferritin and liver magnetic resonance imaging (MRI). In under-transfused children, ferritin underestimates the systemic iron burden [<a href="#rid31">31</a>]. The initial liver MRI should be performed around two years of age, which is used to determine the intensity of chelation therapy. </p><p></p><p class="headingAnchor" id="H1731659138"><span class="h2">Hematopoietic stem cell transplant</span><span class="headingEndMark"> — </span>The options for hematopoietic stem cell transplant (HSCT) should be explored early with the family or caregivers. Matched related donors are found in a minority of cases, in which case HSCT is recommended at approximately two years of age. </p><p>If an HLA-matched related donor is not available:</p><p class="bulletIndent1"><span class="glyph">●</span>Some families or caregivers may elect to pursue pregnancy with preimplantation genetic testing (PGT) to produce an HLA-matched sibling for cord blood transplant. (See  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation", section on 'Umbilical cord blood donors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small number of patients have undergone matched unrelated donor HSCT. Counseling for unrelated donor transplant for ATM should follow the same guidelines as used for beta thalassemia major when discussing success rates, treatment-related mortality, and graft rejection. (See  <a class="medical medical_review" href="/d/html/3554.html" rel="external">"Hematopoietic stem cell transplantation for transfusion-dependent thalassemia"</a>.)</p><p></p><p class="headingAnchor" id="H3186154090"><span class="h2">Correction of congenital anomalies</span><span class="headingEndMark"> — </span>Surgical consultation is arranged early to plan for correction of congenital anomalies [<a href="#rid11">11,13,32</a>]. The common surgical interventions are urethroplasty and orchidopexy. Depending on the severity of urogenital defects, staged procedures can be necessary. (See  <a class="medical medical_review" href="/d/html/113553.html" rel="external">"Hypospadias: Management and outcome"</a> and  <a class="medical medical_review" href="/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management"</a>.)</p><p>Transfusion should be scheduled a few days ahead of surgery to ensure adequate suppression of Hb H. (See <a class="local">'Chronic transfusion program'</a> above.)</p><p class="headingAnchor" id="H2787685141"><span class="h2">Neurodevelopmental assessment</span><span class="headingEndMark"> — </span>All infants should be followed by developmental specialists and also undergo neurologic assessment due to the risk of intrauterine and perinatal brain injury. </p><p>Generalization of neurodevelopmental outcomes is not feasible, as prenatal management is highly variable. Children treated with intrauterine transfusions (IUT) generally have improved long-term neurodevelopmental outcomes when compared with children who did not receive IUT (see <a class="local">'Intrauterine transfusions'</a> above). However, even children treated with IUT have had a period of severe anemia early in gestation (before the diagnosis was made and the anemia corrected) that could potentially have an adverse impact on neurocognitive development. </p><p>Management depends upon the extent of intellectual disability and whether any visual, hearing, or motor deficits are present. (See  <a class="medical medical_review" href="/d/html/6191.html" rel="external">"Intellectual disability (ID) in children: Management, outcomes, and prevention"</a>.)</p><p class="headingAnchor" id="H2091272867"><span class="h2">Health maintenance</span><span class="headingEndMark"> — </span>Children with ATM often exhibit growth retardation, but this may again vary with the quality of prenatal and postnatal care. Attention to diet and monitoring weight gain is important. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Monitoring and management of disease complications'</a>.)</p><p>Children should receive all routine immunizations and preventive care through primary care providers. (See  <a class="medical medical_review" href="/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview"</a>.)</p><p class="headingAnchor" id="H116030488"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H2978874403"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Alpha thalassemia major (ATM) is caused by deletion of all four alpha globin genes (--/--); both parents are alpha<sup>0</sup> thalassemia carriers (--/αα). Fetal hemoglobin (Hb F, alpha2 gamma2) cannot be synthesized without alpha globin, and severe fetal anemia develops. The main hemoglobin is hemoglobin Barts (gamma globin tetramers), which does not transport oxygen. Fetal anemia and hypoxia cause hydrops fetalis, which causes intrauterine demise unless intrauterine transfusions (IUT) are performed. In many regions of Asia, ≥5 percent of the population can be carriers of alpha<sup>0</sup> thalassemia. (See <a class="local">'Overview'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal course</strong> – Prenatal ultrasound findings are consistent with fetal anemia and may include nonimmune hydrops fetalis, increased cardiothoracic ratio, placental enlargement, amniotic fluid abnormalities (oligohydramnios and polyhydramnios), and congenital anomalies. We have observed fetal growth restriction and echogenic bowel. Maternal mirror syndrome can occur. (See <a class="local">'Prenatal manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal evaluation</strong> – Screening of at-risk individuals is discussed separately. (See  <a class="medical medical_review" href="/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p></p><p class="bulletIndent1">For known at-risk pregnancies, chorionic villus sampling or amniocentesis should be offered. For patients with ultrasound evidence of fetal anemia without confirmed molecular diagnosis who are interested in pursuing fetal transfusions, percutaneous umbilical blood sampling (PUBS) should be offered for diagnosis and therapy. A confirmed diagnosis of ATM is followed by nondirective counseling to decide between pregnancy continuation or termination. (See <a class="local">'Prenatal screening and diagnosis'</a> above and <a class="local">'Counseling and decision-making'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prenatal</strong> – For individuals who chose to continue the pregnancy, IUT may be initiated as early as 18 weeks gestation. Simple or exchange transfusion is needed to suppress Hb Barts and improve oxygen delivery. Transfusions are performed every two to three weeks, using volumes based on protocols for hemolytic disease of the fetus and newborn. PUBS is used to monitor the hemoglobin and percentage of Hb Barts. If pregnancy is continued without fetal transfusions, close maternal surveillance is recommended for early recognition of maternal mirror syndrome. Suboptimal prenatal management is associated with preterm birth, fetal growth restriction, cardiorespiratory complications, organomegaly with effusions, anemia, thrombocytopenia, and hyperbilirubinemia. (See <a class="local">'Prenatal'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neonatal</strong> – Delivery should occur in a facility that can provide high-level critical care. Cord blood hemoglobin and Hb Barts are tested at birth; all patients are transfusion dependent. An urgent simple transfusion with 5 to 10 mL/kg of a high-hematocrit red blood cell (RBC) unit should be given initially, with subsequent management depending upon the cardiovascular status and cord blood hemoglobin. (See <a class="local">'Delivery and neonatal period'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Childhood</strong> – Hb Barts is replaced by Hb H (another nonfunctional hemoglobin) over the first few months of life. Chronic transfusion management is similar to beta thalassemia major except for the necessity to account for nonfunctional hemoglobins. The transfusion regimen aims to maintain functional adult hemoglobin (Hb A) &gt;9 g/dL, either by testing hemoglobin fractions at each transfusion or by keeping the pretransfusion total hemoglobin (Hb A plus Hb H) &gt;10.5 g/dL. Iron chelation is started at approximately one year, with careful monitoring for toxicities. (See <a class="local">'Management (infancy and childhood)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-degree relatives (counseling and testing)</strong> – Preconception counseling and prenatal testing is appropriate for parents of an affected child and siblings of that child. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Reproductive testing and counseling'</a> and  <a class="medical medical_review" href="/d/html/138739.html" rel="external">"Gene test interpretation: <i>HBA1 </i>and <i>HBA2 </i>(alpha globin genes)"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Farashi S, Harteveld CL. Molecular basis of α-thalassemia. Blood Cells Mol Dis 2018; 70:43.</a></li><li><a class="nounderline abstract_t">Charoenkwan P, Taweephol R, Sirichotiyakul S, et al. Cord blood screening for alpha-thalassemia and hemoglobin variants by isoelectric focusing in northern Thai neonates: correlation with genotypes and hematologic parameters. Blood Cells Mol Dis 2010; 45:53.</a></li><li><a class="nounderline abstract_t">He S, Zheng C, Meng D, et al. Hb H Hydrops Fetalis Syndrome Caused by Association of the - -(SEA) Deletion and Hb Constant Spring (HBA2: c.427T &gt; C) Mutation in a Chinese Family. Hemoglobin 2015; 39:216.</a></li><li><a class="nounderline abstract_t">Lorey F, Charoenkwan P, Witkowska HE, et al. Hb H hydrops foetalis syndrome: a case report and review of literature. Br J Haematol 2001; 115:72.</a></li><li><a class="nounderline abstract_t">Fucharoen S, Weatherall DJ. Progress Toward the Control and Management of the Thalassemias. Hematol Oncol Clin North Am 2016; 30:359.</a></li><li><a class="nounderline abstract_t">Li CK. New trend in the epidemiology of thalassaemia. Best Pract Res Clin Obstet Gynaecol 2017; 39:16.</a></li><li><a class="nounderline abstract_t">Feuchtbaum L, Carter J, Dowray S, et al. Birth prevalence of disorders detectable through newborn screening by race/ethnicity. Genet Med 2012; 14:937.</a></li><li><a class="nounderline abstract_t">Chui DH, Waye JS. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood 1998; 91:2213.</a></li><li><a class="nounderline abstract_t">King AJ, Higgs DR. Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form of α-thalassemia. Hematology Am Soc Hematol Educ Program 2018; 2018:353.</a></li><li><a class="nounderline abstract_t">Vichinsky EP. Alpha thalassemia major--new mutations, intrauterine management, and outcomes. Hematology Am Soc Hematol Educ Program 2009; :35.</a></li><li><a class="nounderline abstract_t">Songdej D, Babbs C, Higgs DR, BHFS International Consortium. An international registry of survivors with Hb Bart's hydrops fetalis syndrome. Blood 2017; 129:1251.</a></li><li><a class="nounderline abstract_t">Vichinsky EP. Clinical manifestations of α-thalassemia. Cold Spring Harb Perspect Med 2013; 3:a011742.</a></li><li><a class="nounderline abstract_t">Kreger EM, Singer ST, Witt RG, et al. Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. Prenat Diagn 2016; 36:1242.</a></li><li><a class="nounderline abstract_t">Zhang HJ, Amid A, Janzen LA, et al. Outcomes of haemoglobin Bart's hydrops fetalis following intrauterine transfusion in Ontario, Canada. Arch Dis Child Fetal Neonatal Ed 2021; 106:51.</a></li><li><a class="nounderline abstract_t">Chan WY, Leung AW, Luk CW, et al. Outcomes and morbidities of patients who survive haemoglobin Bart's hydrops fetalis syndrome: 20-year retrospective review. Hong Kong Med J 2018; 24:107.</a></li><li><a class="nounderline abstract_t">Tongsong T, Wanapirak C, Sirichotiyakul S, Chanprapaph P. Sonographic markers of hemoglobin Bart disease at midpregnancy. J Ultrasound Med 2004; 23:49.</a></li><li><a class="nounderline abstract_t">MacKenzie TC, Amid A, Angastiniotis M, et al. Consensus statement for the perinatal management of patients with α thalassemia major. Blood Adv 2021; 5:5636.</a></li><li><a class="nounderline abstract_t">Sanguansermsri T, Thanaratanakorn P, Steger HF, et al. Prenatal diagnosis of hemoglobin Bart's hydrops fetalis by HPLC analysis of hemoglobin in fetal blood samples. Southeast Asian J Trop Med Public Health 2001; 32:180.</a></li><li><a class="nounderline abstract_t">Peddi NC, Avanthika C, Vuppalapati S, et al. A Review of Cordocentesis: Percutaneous Umbilical Cord Blood Sampling. Cureus 2021; 13:e16423.</a></li><li><a class="nounderline abstract_t">Horvei P, MacKenzie T, Kharbanda S. Advances in the management of α-thalassemia major: reasons to be optimistic. Hematology Am Soc Hematol Educ Program 2021; 2021:592.</a></li><li><a class="nounderline abstract_t">Lee HH, Mak AS, Poon CF, Leung KY. Prenatal ultrasound monitoring of homozygous α0-thalassemia-induced fetal anemia. Best Pract Res Clin Obstet Gynaecol 2017; 39:53.</a></li><li><a class="nounderline abstract_t">Li X, Zhou Q, Zhang M, et al. Sonographic markers of fetal α-thalassemia major. J Ultrasound Med 2015; 34:197.</a></li><li><a class="nounderline abstract_t">Vichinsky E. Advances in the treatment of alpha-thalassemia. Blood Rev 2012; 26 Suppl 1:S31.</a></li><li><a class="nounderline abstract_t">Schwab ME, Lianoglou BR, Gano D, et al. The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry. Blood Adv 2023; 7:269.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM), Norton ME, Chauhan SP, Dashe JS. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol 2015; 212:127.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT02986698 (Accessed on August 21, 2021).</li><li><a class="nounderline abstract_t">Amid A, Chen S, Brien W, et al. Optimizing chronic transfusion therapy for survivors of hemoglobin Barts hydrops fetalis. Blood 2016; 127:1208.</a></li><li><a class="nounderline abstract_t">Elalfy MS, El-Beshlawy A, Adly A, et al. Safety and efficacy of early-start deferiprone in infants and young children with beta-thalassemia (START Study). Blood 2021; 138 (Supplement 1):3070.</a></li><li><a class="nounderline abstract_t">Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739.</a></li><li class="breakAll">https://thalassemia.com/documents/monitoring-deferasirox-therapy.pdf (Accessed on October 18, 2021).</li><li><a class="nounderline abstract_t">Amid A, Chen S, Athale U, et al. Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis. Haematologica 2018; 103:e184.</a></li><li><a class="nounderline abstract_t">Abuelo DN, Forman EN, Rubin LP. Limb defects and congenital anomalies of the genitalia in an infant with homozygous alpha-thalassemia. Am J Med Genet 1997; 68:158.</a></li></ol></div><div id="topicVersionRevision">Topic 131582 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032940" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular basis ofα-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299254" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cord blood screening for alpha-thalassemia and hemoglobin variants by isoelectric focusing in northern Thai neonates: correlation with genotypes and hematologic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25897478" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hb H Hydrops Fetalis Syndrome Caused by Association of the - -(SEA) Deletion and Hb Constant Spring (HBA2: c.427T &gt; C) Mutation in a Chinese Family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722414" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hb H hydrops foetalis syndrome: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27040959" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Progress Toward the Control and Management of the Thalassemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27847257" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : New trend in the epidemiology of thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766612" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Birth prevalence of disorders detectable through newborn screening by race/ethnicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516118" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504332" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form ofα-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008180" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Alpha thalassemia major--new mutations, intrauterine management, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28057638" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : An international registry of survivors with Hb Bart's hydrops fetalis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543077" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical manifestations ofα-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27862048" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32616558" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outcomes of haemoglobin Bart's hydrops fetalis following intrauterine transfusion in Ontario, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29632273" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcomes and morbidities of patients who survive haemoglobin Bart's hydrops fetalis syndrome: 20-year retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756353" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sonographic markers of hemoglobin Bart disease at midpregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34749399" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Consensus statement for the perinatal management of patients withαthalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11485083" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prenatal diagnosis of hemoglobin Bart's hydrops fetalis by HPLC analysis of hemoglobin in fetal blood samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34422463" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A Review of Cordocentesis: Percutaneous Umbilical Cord Blood Sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34889445" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Advances in the management ofα-thalassemia major: reasons to be optimistic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863915" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prenatal ultrasound monitoring of homozygousα0-thalassemia-induced fetal anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614392" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sonographic markers of fetalα-thalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22631041" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Advances in the treatment of alpha-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36306387" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557883" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557883" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26732098" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Optimizing chronic transfusion therapy for survivors of hemoglobin Barts hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Safety and efficacy of early-start deferiprone in infants and young children with beta-thalassemia (START Study)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028304" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Iron-chelating therapy and the treatment of thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028304" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Iron-chelating therapy and the treatment of thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29371322" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028450" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Limb defects and congenital anomalies of the genitalia in an infant with homozygous alpha-thalassemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
